Jove
Visualize
Contact Us

Related Experiment Videos

Depressing research.

Daniel Roth, Erin Boyle, Darcy Beer

    Lancet (London, England)
    |June 23, 2004
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Grand Challenges in Cross Reality.

    IEEE transactions on visualization and computer graphics·2026
    Same author

    Persistent Vomiting Among Children With Acute Gastroenteritis: A Secondary Analysis of a Randomized Clinical Trial.

    JAMA network open·2026
    Same author

    Evaluating Cutout Rendering Techniques for Pass-Through Embodiment Using a Real-Mirror Metaphor.

    IEEE transactions on visualization and computer graphics·2026
    Same author

    The Influence of Environmental Fidelity on Virtual Presence, Intrinsic Motivation, Cognitive Load and Learning Outcomes in Medical VR.

    IEEE transactions on visualization and computer graphics·2026
    Same author

    MultiCam: On-the-fly Multi-Camera Pose Estimation Using Spatiotemporal Overlaps of Known Objects.

    IEEE transactions on visualization and computer graphics·2026
    Same author

    Reliability in Focus: Trust, Agency, Ownership, and Gaze Behavior in a VR Prosthesis Simulator.

    IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society·2026
    Same journal

    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

    Lancet (London, England)·2026
    Same journal

    The US Ebola response and the future of global health leadership.

    Lancet (London, England)·2026
    Same journal

    Daniel Mason: a tale of change.

    Lancet (London, England)·2026
    Same journal

    The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

    Lancet (London, England)·2026
    Same journal

    Indonesia's health reform: from pandemic mandate to the six pillars of transformation.

    Lancet (London, England)·2026
    Same journal

    LGBTQ+ Russians increasingly avoiding doctors.

    Lancet (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Suppression of negative pediatric antidepressant trials is a crime. Concealing data on serotonin-selective reuptake inhibitor (SSRI) risks and inefficacy constitutes corporate violence.

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology
    • Medical Ethics

    Background:

    • Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for pediatric depression.
    • Concerns exist regarding the suppression of negative clinical trial data for SSRIs in children.
    • This practice raises significant ethical and safety issues in pediatric psychopharmacology.

    Discussion:

    • The intentional withholding of SSRI trial results showing lack of efficacy and increased adverse events in children is ethically indefensible.
    • Analogous to medical malpractice, suppressing critical patient safety data constitutes a severe breach of trust.
    • The pharmaceutical industry's role in obscuring negative SSRI trial outcomes necessitates scrutiny.

    Key Insights:

    • Evidence suggests suppression of negative pediatric SSRI trial publications, excluding fluoxetine.
    Keywords:
    Biomedical and Behavioral Research

    Related Experiment Videos

  • Concealed data indicate potential lack of efficacy and increased risks of serious adverse events.
  • This suppression constitutes a form of corporate violence, prioritizing profit over child safety.

    • Outlook:

    • Urgent calls for transparency in pharmaceutical research and publication practices.
    • Need for regulatory oversight to prevent suppression of critical drug safety data.
    • Re-evaluation of SSRI use in pediatric populations based on complete trial data is imperative.